RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ken Song

Chief Technical Officer

Deborah Charych

Vice President

Derek Cole

Vice President

Gary Li

Vice President

Nicholas Smith

VP - Finance

Kathie Huynh

VP - Operations

Eric Bischoff

Browse more venture capital transactions:

Prev: 6/16/2021: Macrometa venture capital transaction
Next: 6/16/2021: BookClub venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary